Create an Account
  1. Home
  2. Specialty
  3. Cataract & Refractive

On the Horizon: New Options for Treating Presbyopia

On the Horizon New Options for Treating Presbyopia
Media formats available:
Details
Presenters

  • Overview

    Pharmaceutical options for treatment of presbyopia will change the conversations between eye care providers and patients. These drugs are also expected to provide a gateway for more patients to visit eye care providers. The current options simply do not completely satisfy all patients.

    This program will include engaging discussions among the panel members and audience related to underlying mechanisms of presbyopic changes; pharmacological properties of newly emerging presbyopia-correcting drops and their mechanisms of action; and how presbyopia-correcting drops are likely to affect categories of patients based on individual characteristics.

     

    Supported by an unrestricted medical education grant from AbbVie.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Differentiate the underlying mechanisms of presbyopic changes.
    • Interpret the clinical trial experience published in the literature with pharmaceutical and nonpharmaceutical presbyopia-correcting options.
    • Distinguish among the pharmacological properties of newly emerging presbyopia correcting drops and their mechanisms of action.
    • Explain how presbyopia-correcting drops are likely to affect categories of patients based on individual characteristics.
    • Describe the side effects of pharmaceutical approaches to presbyopia correction with other treatment options to debate the pros and cons of each strategy.

    • Accreditation

      Sponsored by

       

      Credit Designation Statement
      Evolve Medical Education LLC (Evolve) is an approved COPE administrator.

      This activity, COPE Activity Number 123023, is accredited by COPE for continuing education for optometrists. 
      This course is approved for 1.25 hours CE. 

      Course # 75786-AS
      Activity # 123023

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Milton M. Hom, OD, FAAO

      Milton M. Hom, OD, FAAO

      Private practice
      Azusa, CA


      Marc Bloomenstein, OD, FAAO

      Marc Bloomenstein, OD, FAAO

      Schwartz Laser Eye Center
      Director of Optometric Services
      Scottsdale, AZ


      April Jasper, OD, FAAO

      April Jasper, OD, FAAO

      Advanced Eyecare Specialists
      West Palm Beach, FL


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

      The following faculty/staff members have the following financial relationships with commercial interests:

      Milton M. Hom, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan/AbbVie, Eyenovia, Novartis, and Visus.Grant/Research Support: Allergan/AbbVie, Eyenovia, Novartis, and Vyluma. Speaker’s Bureau: Allergan/AbbVie.

      Marc Bloomenstein, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bausch + Lomb, BioTissue, Johnson & Johnson Vision, Kala Pharmaceuticals, Ocusoft, Reichert, and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, and Sun.

      April Jasper, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Alcon Vision, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Eyenovia, Sun Pharmaceutical Industries, and Visus. Grant/Research Support: Alcon Vision.

      The Evolve staff and planners have no financial relationships with commercial interests.
      Mark Goerlitz-Jessen, MD, peer reviewer, has no financial relationships with commercial interests.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or AbbVie.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free